The combinatory effect of the decrease in the levels of MCL-1 by dinaciclib plus the inhibition of the remaining members of the BCL-2 family by navitoclax proves particularly effective in SCLC, as it has been shown that SCLC cell lines display addiction to BCL-2, BCL-xL or MCL-1 for survival [35]. The gene discussed is BCL2L1; the disease is small cell lung carcinoma.